People: World Heart Corporation (WHRT.O)

WHRT.O on Consolidated Issue listed on NASDAQ Capital Market

5.80USD
9 Feb 2010
Price Change (% chg)

$-0.34 (-5.54%)
Prev Close
$6.14
Open
$6.15
Day's High
$6.15
Day's Low
$5.56
Volume
10,344
Avg. Vol
5,314
52-wk High
$8.63
52-wk Low
$1.70

view people for:

Summary

Name Age Since Current Position
Estes, Michael 66 2007 Chairman of the Board
Martin, John 55 2009 President, Chief Executive Officer, Director
Brown, Morgan 40 2009 Chief Financial Officer, Vice President - Finance
Jassawalla, Jal 63 2009 Executive Vice President, Chief Technology Officer
Miller, Phillip 61 2004 Vice President - Research & Development
Khanwilkar, Pratap 46 2005 Vice President - Rotary Systems & Business Development
Jansen, Piet 50 2004 Managing Director - Europe
Garriock, William 70 2003 Director
Goertz, Gary 56 2007 Director
Delagardelle, Jeani 53 2008 Director
Hove, Anders 43 2008 Director
Marxe, Austin 69 2008 Director
» Insider Trading

Biographies

Name Description
Estes, Michael Michael Sumner Estes, Ph.D. has served as Director of World Heart Corporation since April 2007 and currently serves as Chair of the Board of Directors. Since 2006, Dr. Estes has been chairman of the Board of Directors of Medical Entrepreneurs II, Inc., a company that develops and manufactures replacement heart valves. From 2001 until 2005, Dr. Estes worked as an independent consultant to Corazon, Inc., a company formed to develop new technology for the less invasive treatment of heart disease caused by calcium deposits. From 1996 to 1999, Dr. Estes was the President and Chief Executive Officer of Orquest, Inc., a company involved in bone replacement technology. From 1979 to 1995, Dr. Estes held executive positions with American Hospital Supply Corporation and Baxter Healthcare Corporation, including responsibility for the worldwide Cardiovascular Group at Baxter HealthCare. Dr. Estes is currently chair of the Board of Directors of nContact Surgical, Inc., a private cardiovascular company.
Martin, John Mr. John Alexander Martin has been appointed as the President, Chief Executive Officer, Director of WorldHeart Corporation on February 5, 2009. Prior to joining the company, Mr. Martin was President of the North American Region and Corporate Vice President of Edwards LifeSciences since 2004. Prior to 2004, he was with Cordis Corporation, a Johnson and Johnson company where he served as Senior Vice President of International and earlier as Vice President of Sales and Marketing. Mr. Martin earned a bachelor's degree from the University of Kentucky at Lexington.
Brown, Morgan Mr. Morgan Brown is Chief Financial Officer, Vice President - Finance of World Heart Corporation. Mr. Brown joins WorldHeart from Lifetree Clinical Research where he was Chief Financial Officer and Senior Vice President since 2008. While at Lifetree Clinical Research, Mr. Brown oversaw the accounting, finance, human resource, facility and information technology departments. Previously, Mr. Brown was with NPS Pharmaceuticals Inc., a Russell 2000 public company, from 2000 to 2008, where he served as Vice President Finance and Treasurer. During his tenure at NPS Mr. Brown was involved in numerous financings as well as merger and acquisition activities.Before NPS, Mr. Brown, worked for KPMG LLP in Salt Lake City. Mr. Brown managed multiple audit engagements, servicing private and publicly owned clients. Mr. Brown is a licensed certified public accountant in Utah and earned a master's degree in business administration from the University of Utah and a bachelor's degree in accounting from Utah State University.
Jassawalla, Jal Jal S. Jassawalla is the Executive Vice President, Chief Technology Officer of World Heart Corporation since February 5, 2009. Mr. Jassawalla has served as the company's director since December 2005 and has been President and Chief Executive Officer since July 2004 until February 2009. From June 2000 to July 2004, Mr. Jassawalla served initially as Senior Vice President and subsequently as Executive Vice President and Chief Technical Officer with responsibility for research and development, clinical affairs, clinical and technical support and quality. Mr. Jassawalla was a co-founder of Novacor Medical Corporation in 1979. He was Vice President of research and development from 1988 to 2000 in Baxter Healthcare Corporation's Novacor Division. He became an employee in June 2000 when WorldHeart acquired the Novacor division of Edwards LifeSciences LLC, a March 2000 spin-off from Baxter Healthcare Corporation. Mr. Jassawalla received his Master of Science in Mechanical Engineering from Stanford University, and an MBA from the University of California, Berkeley, with specialization in Finance. He is a fellow of the American Institute of Medical and Biological Engineering.
Miller, Phillip Phillip J. Miller was appointed Vice President, Research and Development of World Heart Corporation in November 2004. Mr. Miller became an employee in June 2000 when WorldHeart acquired the Novacor Division of Edwards Lifesciences LLC, formerly Baxter Corporation. Previously, he was the Director of Biomedical Engineering at Edwards Lifesciences commencing in 1973.
Khanwilkar, Pratap Pratap S. Khanwilkar joined World Heart Corporation in August 2005 as the Vice President, Rotary Systems and Business Development when WorldHeart purchased MedQuest Products, Inc. Prior to that, Mr. Khanwilkar was Chief Executive Officer and a co-founder of MedQuest from 1993. Mr. Khanwilkar has 24 years of medical device development and commercialization experience, and more than 50 publications in scientific, engineering and medical journals. He was recognized in 2006 as a Fellow of the American Institute of Medical and Biological Engineering, and elected in 2007 as a US representative to the Board of Trustees of the International Society for Rotary Blood Pumps.
Jansen, Piet Piet Jansen, M.D. joined WorldHeart in February 2004 as Chief Medical Officer. He was appointed Managing Director for Europe in July 2004. Prior to joining WorldHeart, Dr. Jansen was the Vice President, Clinical Programs at Orqis International GmbH from 2003 to February 2004. He was Vice President, Clinical Affairs at Jarvik Heart Inc. from 2001 to 2003. From 1997 to 2001, Dr. Jansen worked for the Novacor Division of Edwards Lifesciences LLC, formerly Baxter Corporation.
Garriock, William William C. Garriock has served as Director of World Heart Corporation since December 2003. Since 2003, Mr. Garriock has been a professional company director. From 2000 to 2003 he was the Chairman of MDS SCIEX, the analytical instrument division of MDS Inc. He was also the President of MDS SCIEX from 1994 to 1999. Mr. Garriock was the Executive-at-Large for MDS Inc., a health and life sciences company, from 2000 to 2003. From 1993 to 1994, he was Vice President and Managing Partner (Pharmaceuticals) of MDS Health Ventures Inc. For the previous 18 years, he was the President and CEO of Miles Canada Inc. (now Bayer Canada Inc.), a pharmaceutical, diagnostics and consumer products company. Mr. Garriock is chair of the Board of Directors of Cipher Pharmaceuticals Inc., a pharmaceutical development company listed on the TSX. Mr. Garriock received his B.Comm from the University of British Columbia and an MBA from the Kellogg School of Business of Northwestern University.
Goertz, Gary Gary W. Goertz was appointed to the Board of Directors of World Heart Corporation in June 2007. Since early 2003, Mr. Goertz has been a professional company director. From September 1999 to February 2003, Mr. Goertz served as Executive Vice President, Finance and Chief Financial Officer of MDS Inc. Prior to February 1999, Mr. Goertz was Chief Financial Officer at BCT Telus Communications Inc. Mr. Goertz is a Chartered Accountant for over 30 years.
Delagardelle, Jeani Jeani Delagardelle has served as the Director of WorldHeart Corp since October 2008 and is a Managing Director of New Leaf Venture Partners, a firm which was established by the former health care principals of the Sprout Group. She primarily concentrates on medical device efforts. Ms. Delagardelle currently sits on the Board of Directors of several private companies. Ms. Delagardelle joined Sprout Group in August 2000 and became General Partner in July 2001. Previously, she was a General Partner at Weiss, Peck & Greer Venture Partners where she focused on healthcare/technology investments. Before joining Weiss, Peck & Greer Venture Partners, Ms. Delagardelle spent 15 years in senior marketing, sales, business development and general manager positions in the healthcare industry. She was Vice President of Global Marketing for Target Therapeutics (acquired by Boston Scientific) and spent nine years with the Medi-tech division of Boston Scientific in several senior management roles. In addition, Ms. Delagardelle served as Director of Business Operations for Roche Laboratories and Director of Global Marketing for Cell Pro, Inc. Ms. Delagardelle is the nominee of New Leaf to the Board of Directors of WorldHeart.
Hove, Anders Anders D. Hove, M.D. has served as the Director of WorldHeart Corp since October 2008 and is a general partner of Venrock Associates, a venture capital firm, which he joined in January 2004. From 1996 to 2004, Dr. Hove was a fund manager at BB Biotech Fund, an investment firm. From 2002 to 2003, he also served as the chief executive officer of Bellevue Asset Management, the asset manager of BB Biotech and BB Medtech. Dr. Hove serves on the board of directors of a number of privately held companies. He received an M.D. from the University of Copenhagen, a M.Sc. from the Technical University of Denmark and an MBA from INSEAD. Dr. Hove is the nominee of Venrock to the Board of Directors of WorldHeart.
Marxe, Austin Austin W. Marxe has served as the Director since October 2008, and has served as the President and is a shareholder of AWM Investment Company Inc., ("AWM"). AWM, a Delaware corporation, is a registered Investment Adviser as defined in the Investment Advisory Act of 1940. Mr. Marxe continues to play an integral part in the management of each of Special Situations Fund III, L.P. ("SSF3"), Special Situations Fund III QP, L.P., Special Situations Cayman Fund, L.P., Special Situations Technology Fund, L.P., Special Situations Technology Fund II, L.P., Special Situations Private Equity Fund, L.P. and Special Situations Life Sciences Fund, L.P. (formed in 2005). SSF3 is a registered Investment Company as defined in the Investment Company Act of 1940. Mr. Marxe is a member of each of the general partners of the above Funds and is also a limited partner of MGP and serves as an Individual General Partner of SSF3. Mr. Marxe is the nominee of SSF (as defined below) to the Board of Directors of WorldHeart.

Basic Compensation

Name Fiscal Year Total
Estes, Michael --
Martin, John --
Brown, Morgan --
Jassawalla, Jal 349,765
Miller, Phillip 282,228
Khanwilkar, Pratap 283,103
Jansen, Piet 329,900
Garriock, William --
Goertz, Gary --
Delagardelle, Jeani --
Hove, Anders --
Marxe, Austin --
As Of 30 Dec 2008

Options Compensation

Name Options Value
Estes, Michael 0 0
Martin, John 0 0
Brown, Morgan 0 0
Jassawalla, Jal 1,788,359 1,157,220
Miller, Phillip 325,180 264,600
Khanwilkar, Pratap 0 0
Jansen, Piet 325,000 352,800
Garriock, William 0 0
Goertz, Gary 0 0
Delagardelle, Jeani 0 0
Hove, Anders 0 0
Marxe, Austin 0 0

Insider Trading

Name Shares Traded Price
AUSTIN W MARXE ET AL 388,350 $5.15
DELAGARDELLE JEANI 388,350 $5.15
NEW LEAF VENTURES II L P 388,350 $5.15
HOVE ANDERS D 388,350 $5.15
VENROCK ASSOCIATES V L P 388,350 $5.15
AUSTIN W MARXE ET AL 1,100 $3.25
AUSTIN W MARXE ET AL 300 $3.25
AUSTIN W MARXE ET AL 162 $2.85
AUSTIN W MARXE ET AL 150 $2.76
AUSTIN W MARXE ET AL 200 $2.90
AUSTIN W MARXE ET AL 100 $3.17
AUSTIN W MARXE ET AL 2,000 $3.00
AUSTIN W MARXE ET AL 100 $2.60
AUSTIN W MARXE ET AL 9 $2.59
AUSTIN W MARXE ET AL 1,000 $3.00
AUSTIN W MARXE ET AL 6,300 $2.91
AUSTIN W MARXE ET AL 2,200 $2.75
AUSTIN W MARXE ET AL 5,701 $2.75
AUSTIN W MARXE ET AL 50 $2.60
AUSTIN W MARXE ET AL 283 $2.60
AUSTIN W MARXE ET AL 16,735 $2.69
AUSTIN W MARXE ET AL 11,000 $2.51
AUSTIN W MARXE ET AL 2,200 $2.50
AUSTIN W MARXE ET AL 1,700 $2.50
MINOGUE MICHAEL R 135,000 $2.35
» Full list on Insider Trading
view people for: